Featured Research

from universities, journals, and other organizations

Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma

Date:
December 10, 2002
Source:
Dana-Farber Cancer Institute
Summary:
A drug similar to thalidomide has been found to be promising with fewer side effects for treating patients with recurrent multiple myeloma, an incurable form of bone marrow cancer, according to early data from a clinical study led by Dana-Farber Cancer Institute researchers.

PHILADELPHIA -- A drug similar to thalidomide has been found to be promising with fewer side effects for treating patients with recurrent multiple myeloma, an incurable form of bone marrow cancer, according to early data from a clinical study led by Dana-Farber Cancer Institute researchers.

Related Articles


Paul Richardson, MD, Kenneth Anderson, MD, both of Dana-Farber, and their co-authors will present preliminary safety and effectiveness data from a large multi-center Phase II study of CC-5013 at the annual meeting of the American Society of Hematologists in Philadelphia (Dec. 9, 10:45 a.m., Room 103). Celgene Corporation manufactures CC-5013, which is also known as Revimid TM.

The drug, an analog of thalidomide, was developed to be more potent than thalidomide, while reducing some of thalidomide's dose limiting side effects. Laboratory studies led by Teru Hideshima, MD, at Dana-Farber have shown that CC-5013 not only kills myeloma cells by triggering their innate self-destruct mechanism but also inhibits the myeloma cells ability to localize and grow in the bone marrow. Moreover, it appears to have anti-angiogenic effects and stimulates the immune system to attack myeloma.

"We are encouraged by the responses seen so far, and the relative tolerability of this convenient orally active agent is a real plus for patients," says Richardson.

A Phase I study led by the same Dana-Farber investigators determined a maximum tolerated dose of the drug. The new study, which began earlier this year, compared two therapeutic regimens: one in which patients took 15 mg. of the drug twice daily for three weeks followed by a week of rest, and one in which patients followed the same schedule but with 30 mg. as a once daily dose. Dexamethasone could be added in patients in whom CC-5013 alone was not proving beneficial as laboratory studies have suggested that the two agents combined have at least additive activity in myeloma.

Preliminary results from the trial show that there is significant anti-myeloma activity with measurable responses in about 50 percent of evaluable patients treated to date. The drug has been well tolerated, with evidence that the daily dosing regimen has fewer side effects than the twice daily schedule, but equal activity.

Dana-Farber Cancer Institute (http://www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma." ScienceDaily. ScienceDaily, 10 December 2002. <www.sciencedaily.com/releases/2002/12/021210074407.htm>.
Dana-Farber Cancer Institute. (2002, December 10). Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma. ScienceDaily. Retrieved January 30, 2015 from www.sciencedaily.com/releases/2002/12/021210074407.htm
Dana-Farber Cancer Institute. "Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma." ScienceDaily. www.sciencedaily.com/releases/2002/12/021210074407.htm (accessed January 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, January 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Oxfam Calls for Massive Aid for Ebola-Hit West Africa

Oxfam Calls for Massive Aid for Ebola-Hit West Africa

AFP (Jan. 29, 2015) Oxfam International has called for a multi-million dollar post-Ebola "Marshall Plan", with financial support given by wealthy countries, to help Guinea, Sierra Leone and Liberia to recover. Duration: 01:10 Video provided by AFP
Powered by NewsLook.com
Are We Winning The Fight Against Ebola?

Are We Winning The Fight Against Ebola?

Newsy (Jan. 29, 2015) The World Health Organization announced the fight against Ebola has entered its second phase as the number of cases per week has steadily dropped. Video provided by Newsy
Powered by NewsLook.com
Calif. Health Officials Campaign Against E-Cigarettes

Calif. Health Officials Campaign Against E-Cigarettes

Newsy (Jan. 29, 2015) The California Health Department says e-cigarettes are a public health risk for both smokers and those who inhale e-cig smoke secondhand. Video provided by Newsy
Powered by NewsLook.com
Measles Scare Sends 66 Calif. Students Home

Measles Scare Sends 66 Calif. Students Home

AP (Jan. 29, 2015) Officials say 66 students at a Southern California high school have been told to stay home through the end of next week because they may have been exposed to measles and are not vaccinated. (Jan. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins